Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study

Wang, Feiyang; Huang, Li; Zhang, Jinyan; Fan, Junwei; Wu, Heshui; Xu, Junming

doi:10.7150/jca.60340



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(17):5338-5344. doi:10.7150/jca.60340 This issue Cite

Research Paper

Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study

Feiyang Wang¹, Li Huang¹, Jinyan Zhang¹, Junwei Fan¹, Heshui Wu², Junming Xu^1✉

1. Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
2. Department of Pancreatic Surgery, Wuhan Uniom Hospital, Huazhong University of Science and Technology, Wuhan, China.

Citation:

Wang F, Huang L, Zhang J, Fan J, Wu H, Xu J. Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study. J Cancer 2021; 12(17):5338-5344. doi:10.7150/jca.60340. https://www.jcancer.org/v12p5338.htm

Other styles

Abstract

Background: Pancreatic cancer (PC) is one of the most aggressive and lethal malignancies in the world. High cholesterol intake may have a certain association with an elevated risk of PC, though dyslipidemia in PC patients has rarely been reported. In this study, we compared serum lipids levels between PC and non-PC tumor patients and assessed their prognostic value in PC.

Methods: 271 patients treated at Wuhan Union Hospital from January 2012 to December 2016 and 204 individuals at Shanghai General Hospital from January 2018 to December 2019 were recruited. Their demographic parameters, laboratory data, pathological information, and clinical outcomes were extracted and analyzed. The mRNA expressions of related lipoprotein, low density lipoprotein receptor (LDLR) and high density lipoprotein binding protein (HDLBP), in PC tissues and paired noncancerous tissues and follow-up information were assessed based on the GEO database (GSE15471 and GSE62165) and TCGA database.

Results: A total of 172 non-PC tumor patients and 260 PC patients were finally eligible for our analysis. PC patients exhibited higher levels of serum triglyceride, cholesterol, and low-density lipoprotein (LDL) and a lower serum high-density lipoprotein (HDL) level on admission versus the non-PC tumor group. In PC patients, LDLR mRNA expression was upregulated, and HDLBP mRNA expression was downregulated in cancerous tissues compared to these levels in paired noncancerous tissues. The survival analysis revealed that dyslipidemia had a non-significant association with a poor prognosis, but PC patients with a high LDLR level were at risk of poor survival.

Conclusion: Dyslipidemia is detected in PC patients but has a non-significant relation to PC prognosis. However, LDLR may be a potential predictive marker for PC prognosis.

Keywords: dyslipidemia, pancreatic cancer

Citation styles

APA

Wang, F., Huang, L., Zhang, J., Fan, J., Wu, H., Xu, J. (2021). Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study. Journal of Cancer, 12(17), 5338-5344. https://doi.org/10.7150/jca.60340.

ACS

Wang, F.; Huang, L.; Zhang, J.; Fan, J.; Wu, H.; Xu, J. Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study. J. Cancer 2021, 12 (17), 5338-5344. DOI: 10.7150/jca.60340.

NLM

CSE

Wang F, Huang L, Zhang J, Fan J, Wu H, Xu J. 2021. Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study. J Cancer. 12(17):5338-5344.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.